Safety · Paris

France warns of 300,000 unsafe condoms and urges STI testing after recalls

French health and anti-fraud agencies recalled 260,000 defective condoms and flagged 30 online product lines, advising users to take pregnancy and STI tests.

AI text based on reports by Franceinfo, Il Messaggero, Ziare.com and other publishers. Changed . How it is made

For membersThe first 30 seconds for everyone. Synthetic voice (AI).

In brief

Paris · France
How it came to this
  1. Late May 2026Regulators initiate first wave of product recalls for defective condoms
  2. Early August 2026Second recall campaign begins after laboratory tests confirm defects
  3. 21 AugDGCCRF and DGS publish joint nationwide warning for 300,000 condoms

Joint health alert and testing advisory

French health and anti-fraud regulators issued a nationwide alert on 21 August 2026 regarding roughly 300,000 defective and non-compliant condoms sold in retail shops, pharmacies, and digital marketplaces. The Directorate-General for Health (DGS) alongside the consumer fraud watchdog DGCCRF warned that defective contraceptives present acute risks of unintended pregnancies and sexually transmitted infections. Health authorities advised individuals who used the affected batches to undergo screening for sexually transmitted diseases and perform a pregnancy test if experiencing a delayed menstrual cycle. The public warning follows a sequence of market interventions that began in late May 2026, targeting both uncertified imports and certified products that failed laboratory stress tests.

Physical recalls and laboratory test failures

Government testing laboratories examined condom models distributed through pharmacies and retail stores, discovering structural failures in products that had previously obtained the European CE conformity seal. Around 260,000 units were subject to product recalls launched between late May and early August 2026. Official laboratory analyses revealed that one product line exhibited an elevated risk of bursting, while another demonstrated the presence of perforations. The discovery prompted withdrawals from brick-and-mortar pharmacies, supermarkets, and specialty shops, challenging consumer assumptions that in-store stock is automatically risk-free. Regulators stressed that barrier integrity is essential to public health, particularly in France, where condoms are distributed widely as a first line of sexual health defense.

E-commerce distribution and regulatory breaches

Beyond defective physical stock, market surveillance uncovered 30 separate condom product lines listed across online marketplaces without required European Economic Area certifications. Regulators confirmed that roughly 1,000 boxes, containing more than 40,000 condoms, were purchased by consumers before intervention. The vast majority of these items originated from Asian vendors and lacked CE markings, third-party conformity evaluations, and French-language packaging or safety instructions. In response to regulatory orders, online platforms took down 36 active listings immediately and informed their third-party merchants. Several platforms also pledged to tighten their algorithmic filtering systems and merchant verification rules for medical devices.

Breakdown of non-compliant and recalled condoms by categoryunits
Recalled CE-marked stock (burst or perforation risk)
260000 units
Sold online without CE marking
40000 units

Data from the article text

Affected brands and corporate response

The official consumer alert portal Rappel Conso listed several affected product lines, including Okamoto 002 and 003 produced by Japanese manufacturer Okamoto Industries, Sagami Original 002, Friday Bae by Passage du Desir, and My Lubie. These products had circulated through online platforms like Amazon as well as retail chains such as Monoprix, Nuoo, Mademoiselle Bio, Ayanature, and physical pharmacies. In France, people aged up to 25 are entitled to free condoms in pharmacies without a prescription, increasing public focus on supply chain compliance across both retail and digital channels. Pierre Lagache, chief executive of French brand My Lubie, explained his company's protocol following an anomalous test result.

“We are talking about a medical device: at the slightest doubt, we withdraw it from the market without waiting.”

Pierre Lagache

Lagache stated that My Lubie withdrew the single affected batch on its own initiative as a precautionary step, noting that the manufacturer's own subsequent analyses showed conformity and that no customer harm had been reported to date.

Ask about this text

Sources and context

Places
Paris

Pollar is free and carries no ads in the text. Its members keep it going.

Support Pollar